TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05903092: MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Sponsor: Hirva Mamdani · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 84 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT05903092 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05903092 Rescue Dossier →